Aventis Arava hepatotoxicity
Aventis alerts physicians to Arava (leflunomide) hepatotoxicity labeling revisions for the rheumatoid arthritis agent in "Dear Doctor" letter. The changes, which include a severe liver injury warning and more specific liver function monitoring directions, were added to labeling this summer (1"The Pink Sheet" June 23, 2003, p. 7)...
You may also be interested in...
Arava labeling has been updated to include more explicit liver function monitoring directions
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.